Zymeworks Inc
ZYME16.490USD
+0.620+3.91%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
1.16BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Zymeworks Inc Unternehmen
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Unternehmensinformationen
BörsenkürzelZYME
Name des UnternehmensZymeworks Inc
IPO-datumJun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
Anzahl der mitarbeiter280
WertpapierartOrdinary Share
GeschäftsjahresendeJun 24
Addresse108 Patriot Drive, Suite A
StadtMIDDLETOWN
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl19709
Telefon13022748744
Websitehttps://www.zymeworks.com/
BörsenkürzelZYME
IPO-datumJun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Neil Gallagher, M.D., Ph.D.
Dr. Neil Gallagher, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Andere
47.10%
Aktionäre
Aktionäre
Anteil
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Andere
47.10%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
50.52%
Investment Advisor
23.12%
Hedge Fund
18.92%
Research Firm
5.96%
Private Equity
1.70%
Individual Investor
0.81%
Venture Capital
0.45%
Pension Fund
0.30%
Sovereign Wealth Fund
0.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
2023Q1
340
64.28M
100.47%
-34.07M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
EcoR1 Capital, LLC
22.97M
30.69%
+5.09M
+28.44%
Jun 26, 2025
Rubric Capital Management LP
4.34M
5.8%
+421.11K
+10.75%
Mar 31, 2025
BVF Partners L.P.
4.31M
5.76%
--
--
Mar 31, 2025
Redmile Group, LLC
4.79M
6.4%
-51.52K
-1.06%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.30M
4.42%
-169.56K
-4.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
4.54%
-93.86K
-2.69%
Mar 31, 2025
The Vanguard Group, Inc.
1.76M
2.35%
-718.49K
-28.98%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
2.20M
2.94%
+222.17K
+11.25%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.38M
1.85%
+812.87K
+142.68%
Mar 31, 2025
UBS Asset Management (Americas) LLC
1.60M
2.14%
+1.60M
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
1.13%
Tema Oncology ETF
1.13%
iShares Micro-Cap ETF
0.14%
Federated Hermes MDT Small Cap Core ETF
0.13%
WisdomTree US SmallCap Quality Growth Fund
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Biotechnology ETF
0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
SPDR S&P International Small Cap ETF
0.06%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.13%
Tema Oncology ETF
Anteil1.13%
iShares Micro-Cap ETF
Anteil0.14%
Federated Hermes MDT Small Cap Core ETF
Anteil0.13%
WisdomTree US SmallCap Quality Growth Fund
Anteil0.1%
ProShares Ultra Nasdaq Biotechnology
Anteil0.1%
iShares Biotechnology ETF
Anteil0.09%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.09%
Invesco Nasdaq Biotechnology ETF
Anteil0.09%
SPDR S&P International Small Cap ETF
Anteil0.06%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
